Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Page Not Found
Cart summary

You have no items in your shopping cart.

PF-3845

SKU: orb1301124

Description

PF-3845 is a potent and selective irreversible inhibitor of fatty acid amide hydrolase (FAAH), exhibiting a Ki of 230 nM with minimal activity against FAAH2. It is widely used as a pharmacological tool in vitro and in vivo to investigate the endocannabinoid system, pain, and inflammation.

Research Area

Cell Biology, Metabolism Research, Neuroscience

Images & Validation

Key Properties

CAS Number1196109-52-0
MW456.46
Purity98.00% (May vary between batches)
FormulaC24H23F3N4O2
SMILESFC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1
TargetAutophagy,FAAH
SolubilityEthanol:22.8 mg/mL (49.95 mM);DMSO:100 mg/mL (219.08 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (8.76 mM)

Bioactivity

Target IC50
FAAH:230 nM(Ki)
In Vivo
PF-3845 treated mice (10 mg/kg, i.p.) shows rapid and complete inactivation of FAAH in the brain, as judged by competitive activity-based protein profiling (ABPP) with the serine hydrolase-directed probe fluorophosphonate (FP)-rhodamine. PF-3845 shows a long duration of action up to 24 hour. PF-3845-treated mice also shows dramatic (>10-fold) elevation in brain levels of AEA and other NAEs (N-pamitoyl ethanolamine [PEA] and N-oleoyl ethanolamine [OEA]). FAAH is AEA-degrading enzyme fatty acid amide hydrolase. PF-3845 (1–30 mg/kg, oral administration [p.o.]) causes a dose dependent inhibition of mechanical allodynia with a minimum effective dose (MED) of 3 mg/kg (rats are analyzed at 4 hour post dosing with PF-3845). At higher doses (10 and 30 mg/kg), PF-3845 inhibits pain responses to an equivalent, if not greater, degree than the nonsteroidal anti-inflammatory drug naproxen (10 mg/kg, p.o.). PF-3845 (10 mg/kg, i.p.) significantly reverses LPS-induced tactile allodynia, but doesn't modify paw withdrawal thresholds in the saline-injected paw.
In Vitro
PF-3845 selectively inhibits FAAH by carbamylating FAAH's serine nucleophile.

Storage & Handling

Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

pain, inhibit, inflammation, Inhibitor, Fatty acid amide hydrolase, fatty, FAAH, hydrolase, depression, anxiety, amide, Autophagy, acid, PF-3845, PF3845, PF 3845, sensation

Similar Products

  • PF-3845 [orb1226827]

    >98% (HPLC)

    1196109-52-0

    456.46

    C??H??F?N?O?

    1 g, 500 mg, 200 mg, 25 mg, 10 mg, 50 mg, 100 mg, 2 mg, 5 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

PF-3845 (orb1301124)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

2 mg
$ 80.00
1 ml x 10 mM (in DMSO)
$ 100.00
5 mg
$ 100.00
10 mg
$ 140.00
25 mg
$ 260.00
50 mg
$ 420.00
100 mg
$ 630.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry